|Bid||39.97 x 1300|
|Ask||39.99 x 1800|
|Day's Range||39.92 - 40.02|
|52 Week Range||33.26 - 42.40|
|Beta (5Y Monthly)||0.36|
|PE Ratio (TTM)||13.62|
|Earnings Date||Feb 01, 2017 - Feb 06, 2017|
|Forward Dividend & Yield||2.17 (5.35%)|
|Ex-Dividend Date||May 20, 2021|
|1y Target Est||47.77|
Andy Slavitt, former White House COVID-19 Response Team adviser, author of ‘PREVENTABLE: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response’, joins Yahoo Finance to discuss the COVID-19 response in the U.S. and the Supreme court upholding the Affordable Care Act.
(Bloomberg) -- Lyell Immunopharma Inc., a cancer drug developer backed by GlaxoSmithKline Plc and Celgene Corp., seesawed in its trading debut after raising $425 million in an initial public offering.The shares opened up 10% from the $17 IPO price and then fell as much as 12% Thursday in New York trading. They closed down 0.7% to $16.89, giving the company a market value of about $4.1 billion. Lyell sold 25 million shares Wednesday after marketing them for $16 to $18.The California company, base
CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.